<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>47 HIV-positive male patients with cutaneous <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> (KS) were treated with recombinant interferon alpha-2A (IFN) in an open, prospective study </plain></SENT>
<SENT sid="1" pm="."><plain>45 patients received 18 million I.U </plain></SENT>
<SENT sid="2" pm="."><plain>IFN s.c. daily for the first three months </plain></SENT>
<SENT sid="3" pm="."><plain>From the fourth month, the patients received 18 million I.U </plain></SENT>
<SENT sid="4" pm="."><plain>IFN s.c. three times weekly </plain></SENT>
<SENT sid="5" pm="."><plain>Four of the 45 patients withdrew from therapy because of side effects during the first weeks (weeks 2 to 6) of treatment </plain></SENT>
<SENT sid="6" pm="."><plain>The remaining 41 patients were treated for a minimum period of two years or until their <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Two further patients received 36 million I.U </plain></SENT>
<SENT sid="8" pm="."><plain>IFN daily for three months </plain></SENT>
<SENT sid="9" pm="."><plain>After three months of IFN therapy we observed complete remission (CR) in five of the 41 patients (12%), partial remission (PR) in seven patients (17%), stable disease in seven patients (17%) and progressive disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) in 22 patients (54%) </plain></SENT>
<SENT sid="10" pm="."><plain>The mean survival time from the beginning of IFN therapy to date is 26 months for the 19 responders (patients with CR, PR or SD; six are still alive) and nine months for the 22 non-responders (patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>; <z:hpo ids='HP_0000001'>all</z:hpo> died) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">Recurrence of tumor</z:e> progression occurred in 15 of the 19 responders after an average of ten months of continuous IFN therapy </plain></SENT>
<SENT sid="12" pm="."><plain>The longest time of survival in this group is 54 months up to now </plain></SENT>
<SENT sid="13" pm="."><plain>Of the four remaining patients, <z:hpo ids='HP_0000001'>all</z:hpo> in the CR group, two died after 24 and 26 months of IFN therapy, without any recurrence of KS growth (causes of <z:hpo ids='HP_0011420'>death</z:hpo>: Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and unknown) </plain></SENT>
<SENT sid="14" pm="."><plain>The two other patients, both still alive, have not suffered any <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrence of tumor</z:e> progression after 40 and 41 months, respectively.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>